Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-40

Joel, you do not really understand what a randomised blind trial (which this was) is meant to do. It is not to give a pass or a fail, a yes or a no, a one or a zero. It is to expose the truth, the reality of how well the drug works, in a large enough sample of people to make it meaningful.
The interpretation of the data is where it becomes troublesome. Here, SPL have chosen to highlight strong positive data for the age group 45+. Why? Because that probably is the sweet spot for maximum commercial success. No point trying to selling Viraleze to young people. But 45 and over are likely to get good results and give positive feedback. You could aim it at 60+ and get even better data but lose out on the 45-60 market.
It would be nice to think Viraleze would be effective for everyone, but in reality that would be very unlikely. So don’t think of these results as a failure.